A daily pill developed by the US pharmaceutical company Lilly may become a convenient alternative to injectable drugs like ...

Federal law allows compounding pharmacies to make copies of name brand drugs while there’s a supply shortage. But there's a ...

New research found hospital visits from Ozempic and Wegovy are rare, but can be serious. Experts explain the finding and ...

Novo Nordisk A/S (NYSE:NVO) is the manufacturer and distributor of pharma products, though the company is mainly known for ...

Americans spent an estimated $71.7 billion on GLP-1 drugs including Ozempic and Wegovy in 2023, a 500 percent increase from ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

As Senators Chris Van Hollen, Cory Booker, and Congresswoman Alexandria Ocasio-Cortez are showing, there is huge political ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Novo Nordisk (NYSE: NVO) has filed for U.S. approval of an oral version of its blockbuster weight loss drug Wegovy, the company confirmed to BioPharma Dive. The Danish drugmaker disclosed the ...